PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment is a research paper published in Journal for ImmunoTherapy of Cancer (2022). On theSindex it has a DataRank of 0.728. It has been cited 127 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.728
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Bristol Myers Squibb
Grant: Drug supply
National Institutes of Health
Grant: U01 CA176058
National Institutes of Health
Grant: U01 CA224146
National Institutes of Health
Grant: U54 CA217377
National Cancer Institute
Grant: Cancer Target Discovery and Development (CTD2) Net
NCI NIH HHS
Grant: K08 CA248960
NCI NIH HHS
Grant: K08 CA245112
National Institutes of Health
Grant: 5U54CA217377-03
Quantitative and functional characterization of therapeutic resistance in cancer
National Institutes of Health
Grant: 5U01CA176058-09
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center
National Institutes of Health
Grant: 4U01CA224146-02
Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens
Sloan Research Fellowship in Chemistry
Cookies for Kids Cancer
Pew-Stewart Trust
FWCI
12.08
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of PICLS with human cells is the first high throughput screening method for identifying novel compounds that extend lifespan
Additional file 1 of PICLS with human cells is the first high throughput screening method for identifying novel compounds that extend lifespan
Additional file 1 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 1 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 2 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 2 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 3 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 3 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 4 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 4 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 5 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 5 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 6 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 6 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 7 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 7 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 8 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 8 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 9 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
Additional file 9 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation